Takao Koike
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takao Koike has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
- Tatsuya Atsumi
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University Sapporo Japan
11 shared publications Akito Tsutsumi
Hokkaido University
8 shared publicationsKenji Ichikawa
Hokkaido University
7 shared publicationsNaoki Ishiguro
Department of Orthopedic Surgery, Nagoya University School of Medicine, Nagoya, Japan
6 shared publications- Tsutomu Takeuchi
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo
6 shared publications Yoshiya Tanaka
Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
6 shared publications
Latest Publications
- 15 July 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (11) , 1188-1195
Association of Intraerosive Power Doppler Signals Detected by Musculoskeletal Ultrasound With 1-Year Radiographic Progression in Early Rheumatoid Arthritis
Objective: This study aimed to investigate the clinical and ultrasonographic factors associated with radiographic progression at 1 year after treatment initiation in patients with treatment-naïve rheumatoid arthritis (RA). Methods: We consecutively enrolled treatment-naïve patients with RA who presented to our hospital between January 2018 and December 2023. Clinical disease activity indices, musculoskeletal ultrasound (MSUS) findings of 22 joints in the hands and wrists, and radiographic findings were evaluated at baseline and at the 1-year follow-up. Data were analyzed retrospectively. Results: A total of 265 patients were included. The median duration from symptom onset to treatment initiation was 3.6 months. Baseline disease activity was moderate, with mean Simplified Disease Activity Index and Clinical Disease Activity Index values of 21.2 and 19.5, respectively. All patients initiated treatment with conventional synthetic disease-modifying antirheumatic drugs (DMARDs), and treatment was managed according to a treat-to-target strategy. At 1 year after treatment initiation, 110 patients (41.5%) received biologic or targeted synthetic DMARDs. Concurrently, 215 patients (81.1%) maintained radiographic remission of the hands and wrists, defined as a change in the modified total Sharp score (mTSS) of the hand and wrist (Δhand/wrist mTSS) of ≤ 0.5/year. Multivariable logistic regression analysis showed no significant association between clinical factors, including disease activity indices, and radiographic progression. The presence of power Doppler (PD) signals penetrating into bone erosions was the only independent factor associated with lower odds of maintained structural remission (odds ratio 0.20; 95% CI 0.09-0.46; P < 0.001). Conclusion: In treatment-naïve patients with RA, the presence of intraerosive PD signals on MSUS was associated with radiographic progression at 1 year after treatment initiation.
- 15 July 2026
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 53 (11) , 1188-1195
Association of Intraerosive Power Doppler Signals Detected by Musculoskeletal Ultrasound With 1-Year Radiographic Progression in Early Rheumatoid Arthritis
Objective: This study aimed to investigate the clinical and ultrasonographic factors associated with radiographic progression at 1 year after treatment initiation in patients with treatment-naïve rheumatoid arthritis (RA). Methods: We consecutively enrolled treatment-naïve patients with RA who presented to our hospital between January 2018 and December 2023. Clinical disease activity indices, musculoskeletal ultrasound (MSUS) findings of 22 joints in the hands and wrists, and radiographic findings were evaluated at baseline and at the 1-year follow-up. Data were analyzed retrospectively. Results: A total of 265 patients were included. The median duration from symptom onset to treatment initiation was 3.6 months. Baseline disease activity was moderate, with mean Simplified Disease Activity Index and Clinical Disease Activity Index values of 21.2 and 19.5, respectively. All patients initiated treatment with conventional synthetic disease-modifying antirheumatic drugs (DMARDs), and treatment was managed according to a treat-to-target strategy. At 1 year after treatment initiation, 110 patients (41.5%) received biologic or targeted synthetic DMARDs. Concurrently, 215 patients (81.1%) maintained radiographic remission of the hands and wrists, defined as a change in the modified total Sharp score (mTSS) of the hand and wrist (Δhand/wrist mTSS) of ≤ 0.5/year. Multivariable logistic regression analysis showed no significant association between clinical factors, including disease activity indices, and radiographic progression. The presence of power Doppler (PD) signals penetrating into bone erosions was the only independent factor associated with lower odds of maintained structural remission (odds ratio 0.20; 95% CI 0.09-0.46; P < 0.001). Conclusion: In treatment-naïve patients with RA, the presence of intraerosive PD signals on MSUS was associated with radiographic progression at 1 year after treatment initiation.
- Open Access
Comprehensive Review of Antiphospholipid Syndrome: Over Four Decades of Advances and Challenges
Antiphospholipid syndrome (APS), first described in 1983, is a systemic autoimmune disorder characterized by recurrent arterial and venous thrombosis, pregnancy complications, and persistent antiphospholipid antibodies (aPL). Over four decades, significant advancements have been made in understanding APS pathogenesis, diagnostics, and treatment. Key discoveries include the development of standardized anticardiolipin antibody (aCL) assays, the identification of β2-glycoprotein I (β2GPI) as a critical cofactor, and the elucidation of the “two-hit” hypothesis, which explains thrombotic events through a combination of aPL-induced prothrombotic priming and secondary external triggers. Recent research has highlighted the roles of complement activation, neutrophil extracellular traps (NETs), and genetic predispositions shared with systemic lupus erythematosus (SLE). Innovations like the antiphospholipid score (aPL-S) and updated classification criteria, including the 2023 ACR/EULAR guidelines, have improved diagnostic precision and risk stratification. Despite these advances, challenges remain in assay standardization and addressing seronegative APS. Future directions emphasize the integration of multimodal biomarkers, precision diagnostics, and targeted therapies aimed at complement and NET pathways. These efforts aim to achieve individualized care, improving outcomes for APS patients through harmonized diagnostics, mechanistic therapeutics, and data-driven approaches. This review underscores the evolving understanding of APS and its potential for personalized management strategies.
Open AccessComprehensive Review of Antiphospholipid Syndrome: Over Four Decades of Advances and Challenges
Antiphospholipid syndrome (APS), first described in 1983, is a systemic autoimmune disorder characterized by recurrent arterial and venous thrombosis, pregnancy complications, and persistent antiphospholipid antibodies (aPL). Over four decades, significant advancements have been made in understanding APS pathogenesis, diagnostics, and treatment. Key discoveries include the development of standardized anticardiolipin antibody (aCL) assays, the identification of β2-glycoprotein I (β2GPI) as a critical cofactor, and the elucidation of the “two-hit” hypothesis, which explains thrombotic events through a combination of aPL-induced prothrombotic priming and secondary external triggers. Recent research has highlighted the roles of complement activation, neutrophil extracellular traps (NETs), and genetic predispositions shared with systemic lupus erythematosus (SLE). Innovations like the antiphospholipid score (aPL-S) and updated classification criteria, including the 2023 ACR/EULAR guidelines, have improved diagnostic precision and risk stratification. Despite these advances, challenges remain in assay standardization and addressing seronegative APS. Future directions emphasize the integration of multimodal biomarkers, precision diagnostics, and targeted therapies aimed at complement and NET pathways. These efforts aim to achieve individualized care, improving outcomes for APS patients through harmonized diagnostics, mechanistic therapeutics, and data-driven approaches. This review underscores the evolving understanding of APS and its potential for personalized management strategies.
- 1 August 2021
- Published by Elsevier in Journal of Autoimmunity
- Vol. 122, 102675
Clinical relevance of nitrated beta 2-glycoprotein I in antiphospholipid syndrome: Implications for thrombosis risk
- 1 August 2021
- Published by Elsevier in Journal of Autoimmunity
- Vol. 122, 102675
Clinical relevance of nitrated beta 2-glycoprotein I in antiphospholipid syndrome: Implications for thrombosis risk
- Open Access
- 2 September 2017
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 19 (1) , 1-11
High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study
Although both rheumatoid factor (RF) and anticyclic citrullinated peptide antibodies (anti-CCP) are useful for diagnosing rheumatoid arthritis (RA), the impact of these autoantibodies on the efficacy of tumor necrosis factor (TNF) inhibitors has been controversial. The aim of this post hoc analysis of a randomized double-blind study (the RISING study) was to investigate the influences of RF and anti-CCP on the clinical response to infliximab in patients with RA. Methotrexate-refractory patients with RA received 3 mg/kg of infliximab from weeks 0 to 6 and then 3, 6, or 10 mg/kg every 8 weeks from weeks 14 to 46. In this post hoc analysis, patients were stratified into three classes on the basis of baseline RF/anti-CCP titers: “low/low-C” (RF < 55 IU/ml, anti-CCP < 42 U/ml), “high/high-C” (RF ≥ 160 IU/ml, anti-CCP ≥ 100 U/ml), and “middle-C” (neither low/low-C nor high/high-C). Baseline plasma TNF level, serum infliximab level, and disease activity were compared between the three classes. Baseline RF and anti-CCP titers showed significant correlations with baseline TNF and infliximab levels in weeks 2–14. Comparison of the three classes showed that baseline TNF level was lowest in the low/low-C group and highest in the high/high-C group (median 0.73 versus 1.15 pg/ml), that infliximab levels at week 14 were highest in the low/low-C group and lowest in the high/high-C group (median 1.0 versus 0.1 μg/ml), and that Disease Activity Score in 28 joints based on C-reactive protein at week 14 was lowest in the low/low-C group and highest in the high/high-C group (median 3.17 versus 3.82). A similar correlation was observed at week 54 in the 3 mg/kg dosing group, but not in the 6 or 10 mg/kg group. Significant decreases in both RF and anti-CCP were observed during infliximab treatment. RF/anti-CCP titers correlated with TNF level. This might explain the association of RF/anti-CCP with infliximab level and clinical response in patients with RA. Baseline RF/anti-CCP titers may serve as indices that aid infliximab treatment. ClinicalTrials.gov, NCT00691028 . Retrospectively registered on 3 June 2008.
- 2 September 2017
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 19 (1) , 1-11
Open AccessHigh titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study
Although both rheumatoid factor (RF) and anticyclic citrullinated peptide antibodies (anti-CCP) are useful for diagnosing rheumatoid arthritis (RA), the impact of these autoantibodies on the efficacy of tumor necrosis factor (TNF) inhibitors has been controversial. The aim of this post hoc analysis of a randomized double-blind study (the RISING study) was to investigate the influences of RF and anti-CCP on the clinical response to infliximab in patients with RA. Methotrexate-refractory patients with RA received 3 mg/kg of infliximab from weeks 0 to 6 and then 3, 6, or 10 mg/kg every 8 weeks from weeks 14 to 46. In this post hoc analysis, patients were stratified into three classes on the basis of baseline RF/anti-CCP titers: “low/low-C” (RF < 55 IU/ml, anti-CCP < 42 U/ml), “high/high-C” (RF ≥ 160 IU/ml, anti-CCP ≥ 100 U/ml), and “middle-C” (neither low/low-C nor high/high-C). Baseline plasma TNF level, serum infliximab level, and disease activity were compared between the three classes. Baseline RF and anti-CCP titers showed significant correlations with baseline TNF and infliximab levels in weeks 2–14. Comparison of the three classes showed that baseline TNF level was lowest in the low/low-C group and highest in the high/high-C group (median 0.73 versus 1.15 pg/ml), that infliximab levels at week 14 were highest in the low/low-C group and lowest in the high/high-C group (median 1.0 versus 0.1 μg/ml), and that Disease Activity Score in 28 joints based on C-reactive protein at week 14 was lowest in the low/low-C group and highest in the high/high-C group (median 3.17 versus 3.82). A similar correlation was observed at week 54 in the 3 mg/kg dosing group, but not in the 6 or 10 mg/kg group. Significant decreases in both RF and anti-CCP were observed during infliximab treatment. RF/anti-CCP titers correlated with TNF level. This might explain the association of RF/anti-CCP with infliximab level and clinical response in patients with RA. Baseline RF/anti-CCP titers may serve as indices that aid infliximab treatment. ClinicalTrials.gov, NCT00691028 . Retrospectively registered on 3 June 2008.
- Open Access
- 19 January 2017
- Published by Springer Nature in Journal of Digital Imaging
- Vol. 30 (3) , 369-375
Semi-Automated Quantification of Finger Joint Space Narrowing Using Tomosynthesis in Patients with Rheumatoid Arthritis
- 19 January 2017
- Published by Springer Nature in Journal of Digital Imaging
- Vol. 30 (3) , 369-375
Open AccessSemi-Automated Quantification of Finger Joint Space Narrowing Using Tomosynthesis in Patients with Rheumatoid Arthritis
- 1 June 2016
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 89 (1062) , 20150967
Tomosynthesis can facilitate accurate measurement of joint space width under the condition of the oblique incidence of X-rays in patients with rheumatoid arthritis
Objectives:Accurate evaluation of joint space width (JSW) is important in the assessment of rheumatoid arthritis (RA). In clinical radiography of bilateral hands, the oblique incidence of X-rays is unavoidable, which may cause perceptional or measurement error of JSW. The objective of this study was to examine if tomosynthesis, a recently developed modality, can facilitate a more accurate evaluation of JSW than radiography under the condition of oblique incidence of X-rays.Methods:We investigated quantitative errors derived from the oblique incidence of X-rays by imaging phantoms simulating various finger joint spaces using radiographs and tomosynthesis images. We then compared the qualitative results of the modified total Sharp score of a total of 320 joints from 20 RA patients between these modalities.Results:A quantitative error was prominent when the location of the phantom was shifted along the JSW direction. Modified total Sharp scores of tomosynthesis images were significantly higher than those of ...
- 1 June 2016
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 89 (1062) , 20150967
Tomosynthesis can facilitate accurate measurement of joint space width under the condition of the oblique incidence of X-rays in patients with rheumatoid arthritis
Objectives:Accurate evaluation of joint space width (JSW) is important in the assessment of rheumatoid arthritis (RA). In clinical radiography of bilateral hands, the oblique incidence of X-rays is unavoidable, which may cause perceptional or measurement error of JSW. The objective of this study was to examine if tomosynthesis, a recently developed modality, can facilitate a more accurate evaluation of JSW than radiography under the condition of oblique incidence of X-rays.Methods:We investigated quantitative errors derived from the oblique incidence of X-rays by imaging phantoms simulating various finger joint spaces using radiographs and tomosynthesis images. We then compared the qualitative results of the modified total Sharp score of a total of 320 joints from 20 RA patients between these modalities.Results:A quantitative error was prominent when the location of the phantom was shifted along the JSW direction. Modified total Sharp scores of tomosynthesis images were significantly higher than those of ...
- Open Access
- 22 December 2015
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 3 (1) , 129-141
Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study)
There is insufficient evidence regarding the appropriate dose of methotrexate (MTX) required to achieve specific treatment goals in patients with rheumatoid arthritis (RA) receiving biologic drugs in Japan. The present study aimed to assess the dose-response effect of MTX in combination with adalimumab (ADA) to achieve low disease activity (LDA) and/or remission at 24 weeks in RA patients. This analysis used data of the ADA all-case survey in Japan (n = 7740), and 5494 patients who received ADA and MTX were classified into five groups by weighted average MTX dose (>0-3.2 were analyzed for effectiveness by MTX dose. In biologic-naïve patients (n = 1996/3097), LDA/remission rates increased with MTX up to 6-<8 mg/week and then plateaued at higher doses (LDA, p = 0.0440; remission, p = 0.0422). In biologic-exposed patients (n = 1101/3097), LDA/remission rates increased with MTX dose (LDA, p = 0.0009; remission p = 0.0143). The incidences of serious adverse drug reactions (ADRs) and serious infections did not differ by MTX dose, but total ADRs and infections were significantly higher (p < 0.05) with increased MTX doses. The appropriate MTX doses in combination with ADA to achieve LDA and/or remission at week 24 were different between biologic-naïve and biologic-exposed patients with RA, suggesting that 8 mg/week of MTX would be enough for biologic-naïve patients. ClinicalTrials.gov identifier, NCT01076959. AbbVie and Eisai Co., Ltd.
- 22 December 2015
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 3 (1) , 129-141
Open AccessEffect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals: Post Hoc Analysis of Japanese Patients (MELODY Study)
There is insufficient evidence regarding the appropriate dose of methotrexate (MTX) required to achieve specific treatment goals in patients with rheumatoid arthritis (RA) receiving biologic drugs in Japan. The present study aimed to assess the dose-response effect of MTX in combination with adalimumab (ADA) to achieve low disease activity (LDA) and/or remission at 24 weeks in RA patients. This analysis used data of the ADA all-case survey in Japan (n = 7740), and 5494 patients who received ADA and MTX were classified into five groups by weighted average MTX dose (>0-3.2 were analyzed for effectiveness by MTX dose. In biologic-naïve patients (n = 1996/3097), LDA/remission rates increased with MTX up to 6-<8 mg/week and then plateaued at higher doses (LDA, p = 0.0440; remission, p = 0.0422). In biologic-exposed patients (n = 1101/3097), LDA/remission rates increased with MTX dose (LDA, p = 0.0009; remission p = 0.0143). The incidences of serious adverse drug reactions (ADRs) and serious infections did not differ by MTX dose, but total ADRs and infections were significantly higher (p < 0.05) with increased MTX doses. The appropriate MTX doses in combination with ADA to achieve LDA and/or remission at week 24 were different between biologic-naïve and biologic-exposed patients with RA, suggesting that 8 mg/week of MTX would be enough for biologic-naïve patients. ClinicalTrials.gov identifier, NCT01076959. AbbVie and Eisai Co., Ltd.
- 19 December 2014
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 18 (2) , 233-241
Antiphospholipid syndrome: 30 years and our contribution
In 1983, Graham Hughes first described the concept of antiphospholipid syndrome (APS). In 1984, we described the enzyme‐linked immunosorbent assay (ELISA) system which directly detected circulating aCL in patients with systemic lupus erythematosus (SLE) who revealed biological false positive serological test for syphilis. In 1990, three groups, including our group, independently reported the necessity of a cofactor for the binding of autoimmune anticardiolipin antibodies (aCL) to the solid phase phospholipids. β2‐glycoprotein I (β2GPI) was identified as this cofactor. In 1994,the epitope for aCL was shown to develop when β2GPI is adsorbed on polyoxygenated polystyrene plates. In 2000, we described antiprothrombin antibodies bind to prothrombin exposed to immobilized phosphatidylserine and established a phosphatidylserine dependent monoclonal antiprothrombin antibody. In 2004, a novel role of nicked β2GPI was identified in the negative feedback pathway of extrinsic fibrinolysis. Nicked β2GPI was found to bind angiostatin 4.5 and to attenuate its antiangiogenic property. In 2004, we demonstrated that the p38 MAPK pathway mediates induction of the TF gene in stimulated with human monoclonal anti‐ β2GPI antibodies. Very recently, β2GPI was identified as a complement regulator. The cross‐link between complement activation and prothrombotic status in patients with APS has been drawn much attention. Genetic factors are hypothesized to play a role in the susceptibility to APS based on several family studies in patients with antiphospholipid antibodies (aPL) and/or clinical manifestations of APS. The genetics of β2GPI has been extensively studied. 247 Val/Leu polymorphism can affect the conformational change of β2‐GPI and the exposure of the epitopes for aCL. We found that 247 Val was correlated with anti‐β2‐GPI production in patients with primary APS, and 247 Val may be important for β2‐GPI antigenicity. STAT4 SNP in Japanese patients with SLE and/or APS. T allele frequencies in SLE and APS were significantly elevated compared with that in healthy controls. When analyzed only in primary APS patients, T allele frequency was further higher. BANK1, BLK and SNP in 1q25.1 region were associated with not only SLE but also APS in Japanese population. These results suggest that APS and SLE, in part, share a common genetic background.
- 19 December 2014
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 18 (2) , 233-241
Antiphospholipid syndrome: 30 years and our contribution
In 1983, Graham Hughes first described the concept of antiphospholipid syndrome (APS). In 1984, we described the enzyme‐linked immunosorbent assay (ELISA) system which directly detected circulating aCL in patients with systemic lupus erythematosus (SLE) who revealed biological false positive serological test for syphilis. In 1990, three groups, including our group, independently reported the necessity of a cofactor for the binding of autoimmune anticardiolipin antibodies (aCL) to the solid phase phospholipids. β2‐glycoprotein I (β2GPI) was identified as this cofactor. In 1994,the epitope for aCL was shown to develop when β2GPI is adsorbed on polyoxygenated polystyrene plates. In 2000, we described antiprothrombin antibodies bind to prothrombin exposed to immobilized phosphatidylserine and established a phosphatidylserine dependent monoclonal antiprothrombin antibody. In 2004, a novel role of nicked β2GPI was identified in the negative feedback pathway of extrinsic fibrinolysis. Nicked β2GPI was found to bind angiostatin 4.5 and to attenuate its antiangiogenic property. In 2004, we demonstrated that the p38 MAPK pathway mediates induction of the TF gene in stimulated with human monoclonal anti‐ β2GPI antibodies. Very recently, β2GPI was identified as a complement regulator. The cross‐link between complement activation and prothrombotic status in patients with APS has been drawn much attention. Genetic factors are hypothesized to play a role in the susceptibility to APS based on several family studies in patients with antiphospholipid antibodies (aPL) and/or clinical manifestations of APS. The genetics of β2GPI has been extensively studied. 247 Val/Leu polymorphism can affect the conformational change of β2‐GPI and the exposure of the epitopes for aCL. We found that 247 Val was correlated with anti‐β2‐GPI production in patients with primary APS, and 247 Val may be important for β2‐GPI antigenicity. STAT4 SNP in Japanese patients with SLE and/or APS. T allele frequencies in SLE and APS were significantly elevated compared with that in healthy controls. When analyzed only in primary APS patients, T allele frequency was further higher. BANK1, BLK and SNP in 1q25.1 region were associated with not only SLE but also APS in Japanese population. These results suggest that APS and SLE, in part, share a common genetic background.
- 16 September 2014
- Published by SAGE Publications in Lupus
- Vol. 23 (12) , 1332-1334
My contribution, my dream – a look at the future of APS
We found, in 1994, that the epitope for anticardiolipin antibodies (aCL) developed when β2-glycoprotein I (β2GPI) was adsorbed on polyoxygenated polystyrene plates. We also found, in 2009, that the cleaved form of β2GPI (nicked β2GPI) was bound to angiostatin 4.5 and attenuated its antiangiogenic property. We described in 2000 that antiprothrombin antibodies were bound to prothrombin exposed to immobilized phosphatidylserine (aPS/PT) and more than 95% of antiphospholipid syndrome patients who were positive for aPS/PT had lupus anticoagulant. We demonstrated that in the cells stimulated by human monoclonal anti-β2GPI antibodies, p38 mitogen-activated protein kinase phosphorylation was observed in the presence of β2GPI. Furthermore, we found that complement activation was essential for thrombus formation in patients with the antiphospholipid syndrome in vivo.
- 16 September 2014
- Published by SAGE Publications in Lupus
- Vol. 23 (12) , 1332-1334
My contribution, my dream – a look at the future of APS
We found, in 1994, that the epitope for anticardiolipin antibodies (aCL) developed when β2-glycoprotein I (β2GPI) was adsorbed on polyoxygenated polystyrene plates. We also found, in 2009, that the cleaved form of β2GPI (nicked β2GPI) was bound to angiostatin 4.5 and attenuated its antiangiogenic property. We described in 2000 that antiprothrombin antibodies were bound to prothrombin exposed to immobilized phosphatidylserine (aPS/PT) and more than 95% of antiphospholipid syndrome patients who were positive for aPS/PT had lupus anticoagulant. We demonstrated that in the cells stimulated by human monoclonal anti-β2GPI antibodies, p38 mitogen-activated protein kinase phosphorylation was observed in the presence of β2GPI. Furthermore, we found that complement activation was essential for thrombus formation in patients with the antiphospholipid syndrome in vivo.
- 1 September 2014
- Published by Elsevier in Autoimmunity Reviews
- Vol. 13 (9) , 901-908
Obstetric antiphospholipid syndrome: A recent classification for an old defined disorder
- 1 September 2014
- Published by Elsevier in Autoimmunity Reviews
- Vol. 13 (9) , 901-908
Obstetric antiphospholipid syndrome: A recent classification for an old defined disorder